Quarterly report pursuant to Section 13 or 15(d)

NON-CONTROLLING INTEREST (Details)

v3.20.2
NON-CONTROLLING INTEREST (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 24, 2020
May 20, 2020
Apr. 08, 2020
Mar. 24, 2020
Feb. 25, 2020
May 31, 2020
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
NON-CONTROLLING INTEREST (Details) [Line Items]                    
Asset Purchase Agreement, Description of Royalty     As part of the acquired assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and compounds usage. The agreement calls for milestone payments upon marketing authorization (as amended and defined with respect of product in a particular jurisdiction in the territory, the receipt of all approvals from the relevant regulatory authority necessary to market and sell such product in any such jurisdiction, excluding any pricing approval or reimbursement authorization) in any first and second country of $10 million and $5 million, respectively, in addition to 6% royalty payments.               
Shares Issued, Price Per Share (in Dollars per share)   $ 10.00                
Stock Issued During Period, Shares, New Issues (in Shares) 2,187,500 1,068,550     2,500,000          
Stock Issued During Period, Value, New Issues   $ 10,685,500           $ 25,214,311 $ 8,619,278  
Payments of Stock Issuance Costs             $ 182,332,000,000 $ 182,332,000,000    
Equity Method Investment, Ownership Percentage             69.40% 69.40%    
ViralClear [Member]                    
NON-CONTROLLING INTEREST (Details) [Line Items]                    
Payments to Acquire Productive Assets       $ 350,000            
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)       634,910            
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned       $ 3,174,550            
Asset Purchase Agreement, Description of Royalty       In addition, in the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay Trek 10% of the consideration received.As part of the Purchased Assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and compounds usage. The agreement, as amended on September 2, 2020, calls for milestone payments upon marketing authorization (as defined) in any first and second country of $10 million and $5 million, respectively, in addition to 6% royalty payments            
Stock Issued During Period, Shares, Other (in Shares)     259,959              
Shares Issued, Price Per Share (in Dollars per share)     $ 0.001     $ 10.00        
Stock Issued During Period, Shares, New Issues (in Shares)   1,068,550       1,068,550        
Stock Issued During Period, Value, New Issues   $ 10,592,075       $ 10,592,075        
Payments of Stock Issuance Costs   $ 93,425                
Equity Method Investment, Ownership Percentage       69.40%     69.40% 69.40%    
NeuroClear Technologies, Inc ("NeuroClear") [Member]                    
NON-CONTROLLING INTEREST (Details) [Line Items]                    
Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions (in Shares)                   896,690
Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions                   $ 5,011,310